<PAGE>
                                                                   EXHIBIT 10.25


                              EMPLOYMENT AGREEMENT


         THIS EMPLOYMENT AGREEMENT (the "Agreement"), dated as of June 21, 2002,
is made by and between Inveresk Research International Limited, a company
organized under the laws of Scotland under the Companies Acts (Company Number
91725) and having its registered office at Elphinstone Research Centre, Tranent,
EH33 2NE, (the "Company"), and Alastair S. McEwan (the "Executive").

                                   BACKGROUND

         WHEREAS, the Executive currently serves as President-Clinical Americas
of the Company;

         WHEREAS, Inveresk Research Group Limited, a company organized under the
laws of Scotland under the Companies Acts (Company Number SC091725) and having
its registered office at Elphinstone Research Centre, Tranent, EH33 2NE (the
"Parent"), owns all of the issued and outstanding shares of capital stock of the
Company;

         WHEREAS, all of the shareholders of the Parent are parties to that
certain Exchange Agreement by Declaration of Trust, dated as of April 2, 2002
(as the same may be amended from time to time, the "Exchange Agreement"), among
such shareholders, D. J. Paul E. Cowan, as escrow agent, and Inveresk Research
Group, Inc., a Delaware corporation ("New Holdco");

         WHEREAS, upon consummation of the transactions contemplated by the
Exchange Agreement, the Parent will be a direct wholly-owned subsidiary of New
Holdco and the Company will be an indirect wholly-owned subsidiary of New
Holdco;

         WHEREAS, New Holdco intends to sell shares of its common stock by means
of an initial public offering (the "IPO");

         WHEREAS, this Agreement is being executed in anticipation of the
consummation of the IPO;

         WHEREAS, the Company and New Holdco desire that the Executive continue
to be employed by the Company and render services to the Company and New Holdco,
in accordance with the terms and conditions set forth in this Agreement;

         WHEREAS, the Executive desires to be employed by the Company and to
render services to the Company and New Holdco pursuant to the terms of this
Agreement;

         WHEREAS, the services of the Executive are of a special, unique and
unusual character which gives them distinctive value; and

         WHEREAS, in consideration of the benefits to be derived by the
Executive under this Agreement, the Executive is willing to undertake certain
restrictions on the Executive's business activities from and after the effective
date of this Agreement upon the terms and conditions set forth in this
Agreement;

         NOW, THEREFORE, in consideration of the premises and the covenants and
agreements contained in this Agreement and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties to this Agreement, intending to be legally bound, agree as follows:

         Section 1.        Term. The Company hereby employs the Executive
pursuant to the terms set forth in this Agreement and the Executive hereby
accepts employment with the Company pursuant to the terms set forth in this
Agreement. The Executive's employment with the Company pursuant to this
Agreement shall commence as of the date on which the IPO is consummated and
shall continue until this
<PAGE>
Agreement is terminated in accordance with the provisions of Section 5 (the
"Term"). The date on which the Executive's period of continuous employment with
the Company began was June 10, 1996.

         Section 2.        Duties. The Executive shall continue to serve as
President-Clinical Americas of the Company and shall also serve as a Group
Executive Vice President of New Holdco and, in his capacity as such, shall
faithfully perform for the Company and New Holdco the duties normally associated
with said offices, unless otherwise specified by the Chief Executive Officer of
New Holdco (the "CEO"), and shall perform such other duties of an executive,
managerial or administrative nature as shall be specified and designated from
time to time by the CEO. The Executive shall devote substantially all of his
business time and effort to the performance of his duties under this Agreement.
The Executive's normal hours of work are from 9.00 a.m. to 5.00 p.m. (Monday to
Friday) inclusive of 45 minutes for lunch daily. The Executive is expected to
work reasonable overtime when necessary for the performance of his duties
without any entitlement to additional compensation. The Executive's principal
place of work will be the Inveresk Research North Carolina facility but the
Executive will be expected to travel, both within the U.K. and overseas, on
Company business (without any entitlement to additional compensation).

         Section 3.        Other Conditions.

         3.1.     Standard Conditions. The Executive's employment with the
Company shall be subject to the Company's Standard Conditions of Employment, as
in effect from time to time (the "Standard Conditions"), provided that if any
conflict arises between this Agreement and the Standard Conditions, this
Agreement shall control. The Standard Conditions may be modified from time to
time by the Company, provided that the Standard Conditions may not be modified
in any manner that would adversely affect the Executive without the consent of
the Executive.

         3.2.     Disciplinary/Grievance Procedure. The Company's grievance
procedure from time to time in effect and any disciplinary rules applicable to
the Executive will be set out in notices displayed at his place of work or will
otherwise be obtainable from the Company.

         Section 4.        Compensation.

         4.1.     Salary. As consideration for the services that the Executive
shall render to the Company and New Holdco under this Agreement, the Company
shall pay the Executive a salary of $190,000 per year (the "Annual Salary"),
which shall be payable in equal monthly installments in accordance with the
customary payroll practices of the Company applicable to executive officers. The
Annual Salary shall be reviewed no less frequently than annually by the Board of
Directors of New Holdco (the "Board"). The Annual Salary may, in the discretion
of the Board, be increased (but not decreased) at any time and from time to time
by action of the Board. Once increased, any reference to Annual Salary in this
Agreement shall be a reference to such increased amount.

         4.2.     Bonuses.

                  (a) For each fiscal year of the Company ending during the
Term, the Executive shall have the opportunity to receive an annual bonus in an
amount of up to 33 percent of Annual Salary, as determined by the Board.

                  (b) For each fiscal year ending during the Term, the Executive
shall have the opportunity to receive an additional annual performance bonus in
an amount of between 1 and 67 percent of Annual Salary, as determined by the
Board.

         4.3.     Benefits. The Executive shall have the right to participate in
all benefit programs and/or plans granted to senior executives of the Group
Companies, in accordance with the actual programs or plans that the Board may
institute from time to time or as otherwise required under any applicable law.


                                        2
<PAGE>
Subject to the Company's pension policy as in effect from time to time, the
Executive shall be entitled to continue membership or become a member (as the
case may be), and during the Term remain a member of, the pension scheme, known
as the Inveresk Research International Pension and Life Assurance Plan, or any
other executive, senior or other pension scheme in effect from time to time in
which the Executive would be eligible to participate (collectively, the
"Scheme"). The Company shall contribute to the Scheme at the rate required to
accrue for the Executive a pension entitlement of not less than 1/30th of
Notional Salary for each year of employment with the Company. As used in this
Agreement, Notional Salary means L82,200, subject to review by the Board in
January of each year. The Company shall be entitled at any time to amend or
terminate the Scheme or the Executive's membership of the Scheme subject to (i)
providing the Executive with the benefit of an equivalent pension scheme (the
"New Scheme") which shall be, overall, no less favorable to the Executive and
(ii) ensuring that the Executive is in a position, if he so elects, to transfer
his accrued benefits in the Scheme into the New Scheme, as if such pensionable
service had been under the New Scheme. Changes in the rules of any pension
scheme from time to time in force will be notified in writing to the Executive
within one month of such change becoming effective and copies of the rules of
any such pension scheme will be made available to the Executive on application
by him to the Company's secretary. Membership of the Scheme shall include a
death benefit of four times annual salary. Pension and life assurance benefits
granted to the Executive under this Agreement shall, where applicable, be
subject to maximum limits imposed by the Inland Revenue Earnings Cap Regulations
in effect from time to time.

         4.4.     Vacation. The Executive shall be entitled to vacation in each
fiscal year (inclusive of public holidays) in accordance with the table set
forth below, to be taken at such time or times as the Company may approve:

<TABLE>
<CAPTION>
                                                Number of Vacation Days Per Year
                                                   (exclusive of Saturdays and
                     Year of Service                        Sundays)
                     ---------------                        --------
<S>                                             <C>
                        Less than 8                           32
               More than 7 but less than 8                    33
               More than 8 but less than 9                    34
               More than 9 but less than 10                   35
                       More than 10                           37
</TABLE>

         4.5.     Sick Pay. Without prejudice to the Company's rights under
Section 5 below, during any period of absence from work due to sickness or
accident, the Executive shall (after giving the Company when required evidence
satisfactory to the Company of incapacity and continuing incapacity to work) be
entitled to receive all Annual Salary and other benefits due to such Employee
under this Agreement during the first twenty eight weeks of such absence. The
Company shall offset against any such payments made by the Company to the
Executive all statutory sick pay or other similar government benefit to which
the Executive receives by virtue of his employment with the Company and any
payments made to the Executive pursuant to Section 4.7; provided, that after
twenty-eight weeks the payment of Annual Salary to the Executive shall be at the
discretion of the Company.

         4.6.     Expenses. The Executive shall be entitled to reimbursement for
all business expenses incurred by him in the performance of his duties under
this Agreement in accordance with the standard practices of the Company as in
effect from time to time.

         4.7.     Permanent Health Insurance. If the Executive is absent from
work through illness or injury for a continuous period of more than 26 weeks,
the Executive will be entitled to receive a monthly payment (each, a "PHI
Payment") equal to 65% of his Notional Salary, less the monthly single person's
long term state incapacity benefit to which the Executive is entitled at such
time. The Executive shall be


                                        3
<PAGE>
entitled to receive PHI Payments until the earlier of the Executive's return to
work, retirement or death and PHI Payments shall be increased by 5% each year
during the period that they are being paid to the Executive. While the Executive
is receiving PHI Payments the Executive will continue to be a member of the
Scheme and the Company will continue to make contributions to the Scheme on
behalf of the Executive.

         4.8.     Private Medical Insurance. The Company shall pay the premiums
and other costs associated with the provision of private medical insurance for
the Executive and his immediate family at a level which is in accordance with
Company policy as in effect from time to time and at a level commensurate with
the private medical insurance provided to the Executive on the date of this
Agreement.

         4.9.     Repatriation Costs. If the Company terminates the employment
of the Executive under this Agreement, the Company shall reimburse the
Executive, upon the Executive's submission of proof of such expenses, for all
reasonable costs of relocating from the United States to the United Kingdom;
provided that any such costs and expenses have been approved by the CEO, in his
reasonable discretion, prior to being incurred by the Executive.

         4.10.    No Other Compensation. Except as provided in this Section 4,
the Executive shall be entitled to no other compensation for the services
provided by him to the Company and New Holdco under this Agreement.

         Section 5.        Termination.

                  (a) The Executive's employment under this Agreement may be
terminated at any time (i) by the Company or the Executive upon one year's prior
written notice (or any shorter period mutually agreed upon by the parties) or
(ii) by the Company upon payment of one year's Annual Salary in lieu of notice
and it is expressly agreed that payment in lieu of notice shall not constitute a
repudiation of this Agreement by the Company.

                  (b) Upon termination of the Executive's employment, in
addition to Annual Salary which the Company may elect to pay in lieu of notice,
the Executive shall be entitled to receive any Annual Salary and other benefits
(including bonus) earned and accrued under this Agreement prior to the
expiration of the termination notice period and to be reimbursed, in accordance
with Section 4.6, for any business expenses incurred prior to such date. The
Executive shall have no further rights to any other compensation or benefits
under this Agreement on or after the termination of employment.

         Section 6.        Covenants of the Executive.

         6.1.     Noncompetition. In consideration of the salary and benefits to
be derived by the Executive under this Agreement, and to preserve the goodwill
associated with the business of the Company, during the period commencing on the
date of this Agreement and ending (i) if the Company terminates the Executive's
employment under this Agreement, on the date upon which the Executive shall
cease to be an employee of the Company or (ii) if the Executive terminates his
employment under this Agreement, one year following the date of the notice of
termination of the Executive's employment given pursuant to this Agreement, he
shall not for his own benefit or the benefit of any third party, directly or
indirectly, in any capacity, engage in or be financially interested in any
business operation or division of a business that competes, directly or
indirectly, with any material aspect of the Business in the Geographic Area. The
term "Business" means the provision of drug development services, and any and
all other business activities of any Group Company that after the date of this
Agreement become material to the Group Companies taken as a whole and in which
the Executive was actively involved in the course of his employment during the
one-year period prior to the date of termination of the Executive's employment
with the Company. The term "Geographic Area" means any area in North America and
the United


                                        4
<PAGE>
Kingdom where any Group Company has performed services during the one-year
period prior to the date of termination of the Executive's employment with the
Company.

         6.2.     Nondisclosure. The Executive acknowledges that, by reason of
his employment by the Company, he will have access to confidential information
of the Group Companies, including, without limitation, information and knowledge
pertaining to trade know-how, proprietary computer programs, data, client lists,
marketing and other business strategies, methods of operation, sales and profit
figures, pricing information, personnel information, relationships between a
Group Company and those persons, entities and affiliates with which the Group
Companies have contracted and others who have business dealings with them and
other confidential property and information of the Group Companies
(collectively, the "Confidential Information"). The Executive acknowledges that
the Confidential Information is a valuable and unique asset of the Group
Companies and covenants that, during the period commencing on the date of this
Agreement and ending thirty-six months following the date upon which the
Executive shall cease to be an employee of the Company, he will not use any
Confidential Information or disclose any Confidential Information to any person,
firm or corporation (except as his duties under this Agreement may require) and
that all such matters and properties shall be and shall remain the property of
New Holdco, the Company and/or a Group Company, as applicable, and/or their
customers. The obligation of confidentiality imposed by this Section 6.2 shall
not apply to information that (i) is required by law or by a governmental and/or
regulatory authority to be disclosed, (ii) otherwise becomes generally known
without any breach by the Executive of this Agreement, or (iii) is disclosed by
the Executive in a court or other proceeding against New Holdco or the Company
because such disclosure is reasonably required in order to enforce the
Executive's rights under this Agreement; provided, that in any case described in
clause (i) or clause (iii), the Executive shall, at the expense of the Company,
cooperate, if requested by the Company, in seeking a protective order with
respect to, and otherwise preventing further disclosure of, such information.

         6.3.     Nonsolicitation. During the period commencing on the date of
this Agreement and ending one year following the date upon which the Executive
shall cease to be an employee of this Company, the Executive shall not, directly
or indirectly, for himself or for any other person, firm, or other entity,
solicit, interfere with or endeavor to entice away from any Group Company (i)
the customer of any person, firm or other entity that (A) at the date of
termination of the Executive's employment with the Company or during the
one-year period prior to the date of termination of the Executive's employment
with the Company was a customer or client of any Group Company or (B) to the
Executive's knowledge, was negotiating with any Group Company in relation to any
part of its business or (ii) any director, employee or consultant of any Group
Company.

         6.4.     Company Information. All memoranda, notes, lists, records,
property and any other tangible product and documents (and all copies thereof),
whether visually perceptible, machine-readable or otherwise, made, produced or
compiled by the Executive or made available to the Executive concerning the
business of the Company or its affiliates, (i) shall at all times be the
property of the Company (and, as applicable, any affiliates) and shall be
delivered to the Company at any time upon its request, and (ii) upon the
Executive's termination of employment, shall be immediately returned to the
Company.

         Section 7.        Compliance With Other Agreements. The Executive
represents and warrants to the Company that the execution of this Agreement by
the Executive and the Executive's performance of the Executive's obligations
hereunder will not, with or without the giving of notice and/or the passage of
time, conflict with, result in the breach of any provision of or the termination
of, or constitute a default under, any agreement to which the Executive is a
party or by which the Executive is or may be bound.

         Section 8.        Assignment. Neither party shall have the right to
assign this Agreement or any rights or obligations hereunder without the prior
written consent of the other party; provided, that a merger or consolidation of
the Company or a sale or transfer of all or substantially all of the shares or


                                        5
<PAGE>
assets of the Company (and, in the case of such a sale of assets, a related
assignment of this Agreement) shall not be deemed an assignment in violation of
the terms of this Section 8.

         Section 9.        Miscellaneous.

         9.1.     Survival. Anything contained in this Agreement to the contrary
notwithstanding, the provisions of Sections 6.1, 6.2, 6.3, 6.4 and 9 shall
survive termination of this Agreement and any termination of the Executive's
employment hereunder for the periods indicated therein.

         9.2.     Notices. All notices or communications hereunder shall be in
writing (including by facsimile transmission), addressed as follows:

                  (i)      If to the Company to:

                           Inveresk Research International Limited
                           Elphinstone Research Centre
                           Tranent EH33 2NE
                           Scotland
                           Facsimile: 1875 614 555
                           Attention: Chief Executive

                           With a copy to:

                           Inveresk Research Group, Inc.
                           1100 Weston Parkway
                           Suite 100
                           Cary, North Carolina 27513
                           Facsimile: (919) 462 2400
                           Attention: President and Chief Executive Officer

                  (ii)     If to the Executive to him at the address set forth
on the signature page.

Any such notice shall be effective only if delivered personally, by facsimile or
if mailed (first class prepaid recorded delivery letter). All such notices,
requests and other communications will (i) if delivered by facsimile
transmission to the number as provided in this Section 9.2, be deemed given at
the time when the facsimile machine records delivery of such notice, (ii) if
delivered personally to the address as provided in this Section 9.2, be deemed
given upon delivery and (iii) if delivered by first class prepaid recorded
delivery letter to the address as provided in this Section 9.2, be deemed given
upon receipt. Any party from time to time may change its address or other
information for the purpose of notices to that party by giving notice specifying
such change to the other parties hereto.

         9.3.     Section Headings. The section and subsection headings used in
this Agreement are for reference and convenience only and shall not enter into
the interpretation of this Agreement.

         9.4.     No Waiver. Any term or condition of this Agreement may be
waived at any time by the party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly
executed by or on behalf of the party waiving such term or condition. No waiver
by any party of any term or condition of this Agreement, in any one or more
instances, shall be deemed to be or construed as a waiver of the same or any
other term or condition of this Agreement on any future occasion.

         9.5.     Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of Scotland.

         9.6.     Entire Agreement. This Agreement and the Standard Conditions
supersede all prior discussions and agreements between the parties with respect
to the subject matter of this Agreement, and


                                        6
<PAGE>
contain the sole and entire agreement between the parties hereto with respect to
the subject matter of this Agreement.

         9.7.     Amendment. This Agreement may be amended, supplemented or
modified only by a written instrument duly executed by or on behalf of both
parties to this Agreement.

         9.8.     Withholding. The Company shall be entitled to withhold from
any payments or deemed payments any amount of tax withholding it determines to
be required by law.

         9.9.     No Third Party Beneficiaries. This Agreements is solely for
the benefit of the parties hereto and for the benefit of the Group Companies and
shall not be deemed to confer upon other third parties any remedy, claim,
liability, reimbursement, claim of action or other right, except as expressly
provided in this Agreement.

         9.10.    Gender and Person. Words used in this Agreement, regardless of
the number or gender specifically used, shall be deemed and construed to include
any other number, singular or plural, and any other gender, masculine, feminine
or neuter, as the context shall require.

         9.11.    Binding Effect. This Agreement shall be binding upon and inure
to the benefit of the parties and their respective successors, permitted
assigns, heirs, executors and legal representatives.

         9.12.    Interpretation. In this Agreement, words and phrases defined
in Section 736 of the Companies Act 1985 (as amended) shall have the meanings
given to them in that Act. The term "Group Companies" means New Holdco and its
subsidiaries from time to time and "Group Company" means any ones of them.

         9.13.    Employment Rights Act. The information contained in this
Agreement constitutes a written statement of the terms of the Executive's
employment in compliance with the provisions of the Employment Rights Act 1996.











                                       7
<PAGE>
                  IN WITNESS WHEREOF, these presents consisting of this and the
seven preceding pages are executed as follows:


         SIGNED on behalf of Inveresk
         Research International Limited by
         Ian P. Sword, a director, on the
         21st day of June 2002 before this
         witness:



                                                   /s/ Ian P. Sword
                                                   -----------------------------
                                                   Director







         /s/ Ewan Gilchrist
         ---------------------------
         Ewan Caldwell Gilchrist    Full Name
         ---------------------------
         11 Walker Street           Address
         ---------------------------
         Edinburgh
         ---------------------------
         Solicitor                  Occupation
         ---------------------------



         SIGNED by the said Alastair S. McEwan
         on the 21st day of June 2002
         before this witness:



         /s/ Amy E. Carriello                      /s/ Alastair S. McEwan
         ---------------------------               -----------------------------
                                                   Alastair S. McEwan
         Amy E. Carriello           Full Name
         ---------------------------
         200 Park Avenue            Address
         ---------------------------
         New York, NY 10166
         ---------------------------
         Attorney                   Occupation
         ---------------------------






                                       8